

# Advancing innovative precision therapeutics for debilitating and rare diseases

INVESTOR PRESENTATION - AUGUST 2022



# Forward-looking statements

---

Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this presentation may be identified by the use of words such as “expect,” “will,” “estimate,” “project,” “potential,” “positioned,” “advancing,” “planned,” “progression,” “targeting,” “allow,” “identify,” “concluding,” “leader,” “progress,” “underway,” “goal,” or other similar words. Examples of forward-looking statements include, among others, clinical development and strategic development path for NOV004; cash runway and the ability to fund clinical development milestones; the company’s plans to pursue the strategic expansion of its development pipeline, its intent to out-license its legacy neuroscience and antiviral assets, the strategic growth plan, the FDA and clinical development plans and timeline, prospects, and milestone expectations; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety, and efficacy of the company’s product candidate and discovery pipeline; and statements about its ability to obtain, and the timing relating to, further development and/or out-licensing of its legacy neuroscience and antiviral assets, regulatory submissions, and related response and decisions. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this presentation are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.



# Quince Therapeutics today

## Advancing innovative precision therapeutics for debilitating and rare diseases

*Positioned as lead innovator in underserved therapeutic areas addressing major, unmet medical needs across multiple skeletal therapeutic indications*

## Highly differentiated proprietary precision bone-targeting platform

*Extensive preclinical studies demonstrate concentrated drug-targeting promotes more rapid healing with fewer off-target safety concerns*

## Broad potential applicability of lead precision bone growth molecule NOV004

*NOV004 expected to enter Phase 1 study initiation in 2023 with planned progression to osteogenesis imperfecta as lead indication*

## Opportunistic in-licensing and acquisition for strategic pipeline expansion

*Targeting clinical-stage assets in debilitating and rare diseases with compelling clinical data and meaningful commercial opportunity*

# Quince investment highlights

## *Addressing major, unmet medical needs across multiple skeletal indications*

- >18 million fractures annually, >\$50 billion in direct medical costs in U.S. alone
- No approved treatments for nearly ~50K people in U.S. alone with lead OI indication
- Lead innovator with few competitors and strong intellectual property

## *Highly differentiated bone-targeting platform and broad potential applicability of lead molecule NOV004*

- >10 years of preclinical studies de-risks development, demonstrates more rapid healing with fewer off-target safety concern
- NOV004 expected to enter Phase 1 clinical studies in 2023 and progress to lead indication, osteogenesis imperfecta

## *Strategic pipeline expansion through opportunistic in-licensing and acquisition*

- Evaluating clinical-stage assets targeting debilitating and rare diseases
- Must have compelling clinical data/commercial opportunity, clear operational synergy
- Disciplined approach with ability to be selective and competitive

## *Strong cash position expected to fund operations and clinical activities into 2H 2025*

- Approximately \$105 million in cash/equivalents/securities as of 6/30/22
- Restructuring in 1H 2022 optimized organization for operating efficiency
- Ability to fund NOV004's human PoC milestone and strategic pipeline expansion

## *Out-licensing legacy neuroscience and antiviral assets*

- Out-licensing capital-intensive legacy assets –COR 588, 388, 852, 803
- Effort already underway with goal of concluding the process before YE 2022



# Proven and seasoned leadership team



CEO

## Dirk Thye, M.D.

- 20+ years of experience in biotech company creation, R&D and executive leadership
- Agenovir, Cidara, Cerexa and Peninsula



CMO

## Karen Smith, M.D., Ph.D., M.B.A., LL.M

- Previously CMO at Emergent and Jazz
- Led 50+ clinical trials and 20+ product or indication approvals



CBO

## Brendan Hannah, M.B.A.

- 5+ years leading biotech business operations
- Led BD at Agenovir (acquired by Vir for up to \$290M) and involved in \$1B+ in other transactions



Head of  
Discovery

## Stewart A. Low, Ph.D.

- Primary inventor of precision bone disease platform IP
- Visiting scholar, Purdue University



CAO

## Ted Monohon

- 20+ years financial experience in private equity, publicly/privately held companies and major banks
- Deloitte, SOA Projects, X10 Capital Management

*Collective experience represent  
20+ regulatory approvals and more than  
\$20 billion in aggregate acquisitions*



# Addressing major, unmet medical needs

*More than 18 million fractures  
in the U.S. each year*

Leading to more than \$50 billion in  
direct medical costs

*Underserved bone fracture  
opportunity*

Compounded by growing aging population experiencing  
higher rate of life-threatening fractures

*No osteogenesis imperfecta  
treatments approved*

Affects as many as 50,000 people in U.S. alone

*Positioned as a lead innovator*


Underserved therapeutic areas with  
few competitive companies

*Positioned for rapid expansion*


Multiple skeletal therapeutic indications, including fractures,  
spinal fusion, and other severe bone diseases



# Quince robust development pipeline



# Highly differentiated precision bone disease platform




- Capable of delivering small molecules, peptides, or large molecules
- Designed to deliver concentrated drug directly to the site of fracture, disease, and infection
- Promotes more rapid healing with fewer off-target safety concerns in preclinical studies
- More than 10 years of preclinical studies de-risk development path
- Positioned to address major, unmet medical needs across multiple skeletal indications




# Precise drug targeting increases efficacy



Fractures / Grafts



Bone Infection



Bone Cancer /  
Bone Metastases

# NOV004 discovered at Low lab at Purdue University

## Therapeutic Agent


- Abaloparatide payload
- Parathyroid hormone related protein
- Increases bone density and approved for osteoporosis

## Biological Linker

- Links targeting ligand to abaloparatide payload
- Short sequence of amino acids
- Allows payload to interact with receptors on nearby cells

## Targeting Ligand

- Concentrates abaloparatide payload at fracture site
- Sequence of negatively charged glutamic acid
- Binds to hydroxyapatite with high affinity at site of bone trauma



*Uniquely engineered structure delivers anabolic that accelerates repair directly to fracture site*




# NOV004 concentrated drug increases half-life


Drug and Site		Half-Life (Hours)
Non-targeted Drug	Contralateral Femur	1.6
	Fractured Femur	8.8
NOV004	Contralateral Femur	5.7
	<b>Fractured Femur</b>	<b>66.4</b>

NOV004 AUC is 10x that of non-targeted drug at the fracture site


Half-Life of NOV004 in Bone




# NOV004 rapidly builds dense and strong bone



New Bone





Dense Bone



Strong Bone



# NOV004 improves function following fracture



*NOV004 treated mice move earlier, farther, and faster following femoral fractures*



# NOV004 – Phase 1 SAD/MAD planned study design

Study	Subjects	Cohorts	Objectives
SAD	8 Participants (6 active, 2 placebo)	4	<ul style="list-style-type: none"><li>• Single dose treatment, 7-day follow-up</li><li>• Safety and tolerability of NOV004</li><li>• Human PK/PD</li><li>• Radiology</li><li>• Biomarkers</li></ul>
MAD	8 Fracture Patients (6 active, 2 placebo)	3	<ul style="list-style-type: none"><li>• 6-week treatment, 4-week follow-up</li><li>• Safety and tolerability of NOV004</li><li>• Human PK/PD</li><li>• Radiology</li><li>• Biomarkers</li></ul>

*The Phase 1 results will inform if NOV004 will enter multiple Phase 2 studies in broad and rare diseases*



# Upcoming NOV004 development milestones

*Assemble clinical advisory boards for Fracture and Osteogenesis Imperfecta*

Complete by 3Q22

*Investigator and site selection for Phase 1 study*

Initiate in 3Q22

*Final protocol synopsis for Phase 1 study and CRO selection*

Complete by 4Q22

*Complete pre-IND activities*

Complete in 4Q22 to 1Q23  
timeframe

*Submit IND*

Mid-year 2023

*Initiate Phase 1 study*

Mid-year 2023



# Osteogenesis imperfecta targeted as lead indication

## Incidence


20,000-50,000 in the U.S.

Potential for >100 fractures over a lifetime

## OI Advantages

- Efficient clinical development program
- Potential for breakthrough status
- Potential priority review voucher


Positive in vivo efficacy studies in Type I & III OI transgenic mice




# Osteogenesis imperfecta in fracture repair

## OI Type I

Fracture Mineralization




Mechanical Strength




## OI Type III

Fracture Mineralization




Mechanical Strength



# Potential osteogenesis imperfecta fracture prevention

## Strengthening healthy OI Type I femurs




## Whole-body drug distribution

Healthy skeleton



OI III skeleton



# Leading innovator with strong intellectual property

## Foundation

8 patent families covering covering 80+ anabolic agents and 25+ targeting molecules

## Breadth

Genus claims cover major and minor bone anabolic pathways

## Depth

Granted composition of matter claims covering NOV004 and lead compounds

– Coverage of NOV004 and uses until 2041+


## Markets

Global coverage including US, Europe, Japan, Australia, Canada, China



# Opportunistic in-licensing & acquisition of clinic-stage assets

- Evaluating clinical-stage assets targeting debilitating and rare diseases
- Must have compelling clinical data, strong commercial opportunity, and clear operational synergy
- Disciplined approach with ability to be selective and competitive



# Out-licensing legacy neuroscience and antiviral assets

## *Alzheimer's Disease Periodontitis • Oncology*

- **COR588** next generation lysine gingipain inhibitor targeted for Alzheimer's and other *P. gingivalis* associated degenerative diseases
  - Phase 1 SAD/MAD completed: well-tolerated, allows for once daily dosing
- **COR388** (atuzaginstat) potential for non-systemic use in periodontitis and systemic use in select oncology indications for high-risk oral cancers
- **COR852** arginine gingipain inhibitor in early development as backup

## *Coronavirus Infection*

- **COR803** 3CLpro irreversible inhibitor targeted for coronavirus infection
- Reduced viral load of SARS-CoV-2 in mouse model after oral treatment
- Ready for GLP manufacturing/IND-enabling studies

*Out-licensing effort to identify partners already underway with goal of concluding the process before the end of 2022*





## Investment summary

- ✓ *Addressing major, unmet medical needs across multiple skeletal therapeutic indications*
- ✓ *Highly differentiated bone-targeting drug platform and broad applicability of lead molecule NOV004*
- ✓ *Strategic pipeline expansion through opportunistic in-licensing and acquisition of clinical-stage assets*
- ✓ *Strong cash position expected to fund operations and clinical activities into the second half of 2025*
- ✓ *Out-licensing legacy neuroscience and antiviral assets*
- ✓ *Proven and seasoned team with track record of success*

